SFS looks back on a successful year. It achieved solid organic growth of 5.9% in its core business and increased its profitability significantly to 14.4% (adjusted EBITA margin). Moreover, thanks to two acquisitions, SFS established a firm position in the growing medical device market. SFS expects sales to grow by 8-10% in the 2017 financial year.

SFS achieved solid organic growth of 5.9% in its core business in the 2016 financial year. All segments contributed to this growth. They maintained and expanded their market positions. Consolidated sales reached a record high of CHF 1,437 million. This represents an increase of 4.4% from the previous year. Currency movements had a positive effect of 0.9% on reported sales, and changes in the scope of consolidation added 1.5% to the reported sales growth. Sales were reduced by CHF 50 million (3.9%) due to the phase-out of the trading activities, a non-core activity within the Engineered Components segment.

SFS Group AG published this content on 10 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 March 2017 05:55:13 UTC.

Original documenthttp://www.sfs.biz/en/web/medien/medienmitteilungen/news_detail_35922368.html

Public permalinkhttp://www.publicnow.com/view/D624DF8E9955C88E4F3B2EFA2E21461199322405